Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Home
/
update
/
details

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

NextEdge Admin

03 Jan 2025

2 min 31 sec

Atavistik Bio, a biotechnology company pioneering next-generation precision allosteric therapeutics inspired by the body’s natural regulators, has announced a research collaboration with Pfizer. This partnership aims to accelerate the discovery of novel precision allosteric therapeutics to address significant unmet medical needs.

Under the collaboration, Atavistik Bio will utilize its proprietary AMPS™ platform to identify novel allosteric binders for two undisclosed targets chosen by Pfizer. Following the research phase, Pfizer will have the option to license the programs. The financial terms of the agreement remain undisclosed.

“Allostery offers a transformative approach to developing highly selective, effective, and better-tolerated therapies,” said Bryan Stuart, CEO of Atavistik Bio. “By collaborating with Pfizer, we can leverage our ability to discover functional allosteric binding pockets and advance our mission of delivering innovative therapies for patients in need. Alongside this collaboration, we remain committed to progressing our internal pipeline of precision oncology therapeutics.”

Atavistik Bio’s proprietary AMPS™ platform integrates computational and experimental methods to identify functional cryptic pockets across diverse target classes. This discovery engine accelerates the development of small molecules for historically challenging targets, enabling rapid iteration and advancement of novel chemical matter. The platform’s versatility supports therapeutic innovations across various diseases.

Atavistik Bio focuses on precision allosteric therapeutics to meet serious unmet medical needs, particularly in oncology. Its lead candidate, ATV-1601, a selective allosteric inhibitor for solid tumors, is expected to enter clinical trials in early 2025. Backed by top-tier investors and led by an experienced team, Atavistik Bio is poised to transform the therapeutic landscape.